Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O3OK
|
|||
| Former ID |
DCL000577
|
|||
| Drug Name |
Motavizumab
|
|||
| Synonyms |
MEDI-524; Motavizumab (USAN/INN)
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Respiratory syncytial virus infection [ICD-11: 1C80; ICD-9: 79.6] | Phase 3 | [1] | |
| Company |
AstraZeneca
|
|||
| PubChem Substance ID | ||||
| SuperDrug ATC ID |
J06BB17
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Respiratory syncytial virus protein F (RSV F) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00129766) Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children. U.S. National Institutes of Health. | |||
| REF 2 | Motavizumab. Correction in: MAbs. 2010 Sep-Oct; 2(5): 591. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.